[{"id":"6c9623a6-4573-485b-b022-26e539880a69","acronym":"A061202","url":"https://clinicaltrials.gov/study/NCT02004275","created_at":"2021-01-18T09:09:12.624Z","updated_at":"2025-02-25T14:34:26.703Z","phase":"Phase 1/2","brief_title":"Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT02004275 - A061202","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CYP1A2","pipe":" | ","alterations":" Chr t(14;16) • Chr del(1p)","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(14;16) • Chr del(1p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Ninlaro (ixazomib) • dexamethasone • pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":"","study_completion_date":"","last_update_posted":"2023-12-01"}]